Marcia Belvin

USPTO Granted Patents = 11 (Patent Applications = 6)

EPO Patents = 4 (Patent Applications = 5)

Average Co-Inventor Count = 5.8

ph-index = 3

Forward Citations = 75(Granted Patents)

Location History:

Berkeley, CA (US) (2005)
South San Francisco, CA (US) (2012 - 2013)
Albany, CA (US) (2005 - 2017)

Company Filing History:

F. Hoffmann-La Roche Ag

patents

where one patent can have more than one assignee

Years Active: 2005-2017

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9532987 - Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases (2017-01-03),

2. 9107926 - Mutant selectivity and combinations of a phosphoinositide 3-kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer (2015-08-18),

3. 8771942 - SCDs as modifiers of the p53 pathway and methods of use (2014-07-08),

4. 8604014 - Combinations of phosphoinositide 3-kinase inhibitor compounds chemotherapeutic agents, and methods of use (2013-12-10),

5. 8268548 - MAP3Ks as modifiers of the p53 pathway and methods of use (2012-09-18),

6. 8247397 - Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use (2012-08-21),

7. 8153384 - Marks as modifiers of the p53 pathway and methods of use (2012-04-10),

8. 7049088 - PRMTs as modifiers of the p53 pathway and methods of use (2006-05-23),

9. 6972179 - RRP sequences and knockout mice and uses thereof (2005-12-06),

10. 6927022 - HADHs as modifiers of the p21 pathway and methods of use (2005-08-09),

11. 6924117 - Human RRP sequences and methods of use (2005-08-02),

Title: The Innovative Contributions of Marcia Belvin

Introduction

Marcia Belvin, an accomplished inventor based in Albany, California, has made significant strides in the field of medical research and treatment. With a total of 11 patents to her name, Belvin has focused primarily on developing innovative therapies for hyperproliferative diseases, particularly cancer. Her inventions showcase a commitment to addressing some of the most challenging medical issues of our time.

Latest Patents

Belvin's latest patents highlight groundbreaking approaches to cancer treatment. One notable invention is the use of a combination of a MEK inhibitor and an ERK inhibitor for treating hyperproliferative diseases. This invention provides combinations comprising a MEK inhibitor, such as GDC-0973 or GDC-0623, alongside an ERK inhibitor like GDC-0994. These combinations offer promising therapeutic strategies for patients facing hyperproliferative disorders, including cancer.

Additionally, she has developed methods and compositions for treating hyperproliferative disorders using a mutant-selective phosphoinositide 3-kinase (PI3K) inhibitor, GDC-0032, either as a single agent or in conjunction with chemotherapeutic agents. This innovative approach underscores her dedication to enhancing treatment options for patients battling cancer.

Career Highlights

Belvin's career includes significant work at prominent companies in the biotechnology sector. She has contributed her expertise at Exelixis, Inc. and Genentech, Inc. These experiences have allowed her to collaborate on groundbreaking research and development efforts, further enhancing her inventor profile.

Collaborations

Throughout her career, Marcia has worked alongside esteemed colleagues such as Lori Friedman and Gregory D. Plowman. These collaborations have been instrumental in bringing her inventive ideas to fruition and pushing the boundaries of cancer research.

Conclusion

Marcia Belvin's innovative contributions to cancer treatment exemplify the impact of dedicated inventors in the medical field. Her notable patents and collaborations highlight her influential role in developing new therapies to combat hyperproliferative diseases. As research continues to evolve, Belvin’s work will undoubtedly pave the way for novel advancements in the fight against cancer.

This text is generated by artificial intelligence and may not be accurate.